• Oncolytics Biotech Inc., of Calgary, Alberta, completed enrollment in the first stage of its Phase III trial examining Reolysin in combination with paclitaxel and carboplatin in 80 patients with platinum-refractory head and neck cancers.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter